Protara Therapeutics, Inc. — Director's Dealing 2020

Feb 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ArTara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-02-11

Reporting Person: Davis Blaine (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-11	Stock Option (Right to Buy)	$37.30	A	94000	Acquired	2030-02-10	Common Stock (94000)	Direct

Footnotes

F1: 25% of the shares subject to the option vesting upon Mr. Davis's completion of one year of service measured from the grant date and the balance of the shares vesting monthly thereafter for the next three years.